Industry

 FDA to Review First-of-Its-Kind Percutaneous Femoropopliteal Bypass System IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives by providing disruptive therapies for the interventional treatment of vascular disease, today announced the submission of a Premarket Approval (PMA) application requesting approval for the DETOUR System to the U.S. Food … [Read more…]

MENLO PARK, Calif.–(BUSINESS WIRE)–#ChiefBusinessOfficer—Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing a broad pipeline of best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the appointment of Imran Babar, Ph.D., as chief business officer. Dr. Babar is an accomplished industry leader with broad experience in healthcare strategy, life sciences finance, operations and … [Read more…]

Proceeds to support the development of first candidates for IND-enabling studies, as well as expand discovery and RNA chemistry capabilities to address a wider set of serious liver-related diseases. Additional capabilities create one the world’s fastest liver R&D pipelines. In a matter of days, Ochre can identify a novel target, synthesize an RNA therapy, and … [Read more…]

CARLSBAD, Calif.–(BUSINESS WIRE)–$LCTX #LineageCellTherapeutics—Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance to grant a patent for the Company’s U.S. patent application No. 16/750,975, entitled “Dorsally-Derived … [Read more…]

– Collaboration with BeiGene is part of Immune-Onc’s global clinical development strategy targeting the LILRB family of myeloid checkpoints – PALO ALTO, Calif.–(BUSINESS WIRE)–#ILT3–Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced it has entered into a clinical trial collaboration and supply agreement with BeiGene to … [Read more…]

New data demonstrate the potential impact of DecisionDx®-SCC test results to guide risk-aligned patient management plans and increase confidence in disease management decisions FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CSTL–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is presenting data highlighting its portfolio of skin cancer gene expression profile (GEP) … [Read more…]

BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces that Michele Korfin, Chief Operating Officer and Chief Commercial Officer, will present its corporate highlights at the annual Cell & Gene Meeting on the Mesa to be … [Read more…]

LAVAL, Quebec–(BUSINESS WIRE)–BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that an abstract reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming CHEST Annual Meeting, … [Read more…]

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that an article highlighting preclinical data from BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, was published in the Journal of Medicinal Chemistry. The article, titled “Discovery … [Read more…]

Data includes results from five-year multi-center IDE study in U.S. of the M6-C disc that also demonstrated strong clinical performance, safety and patient benefits LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the presentation of long-term evidence highlighting the clinical management of cervical disc … [Read more…]